UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $64.00 target price on the stock.

URGN has been the subject of a number of other research reports. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Tuesday, February 18th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $40.00.

UroGen Pharma Stock Down 3.4 %

Shares of NASDAQ URGN opened at $9.74 on Tuesday. UroGen Pharma has a 1 year low of $9.45 and a 1 year high of $20.70. The firm has a 50-day simple moving average of $10.67 and a two-hundred day simple moving average of $12.09. The company has a market cap of $228.44 million, a P/E ratio of -3.09 and a beta of 1.08. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

Insider Buying and Selling

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Barclays PLC lifted its position in shares of UroGen Pharma by 409.3% in the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after purchasing an additional 48,040 shares during the period. JPMorgan Chase & Co. raised its stake in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after buying an additional 49,318 shares in the last quarter. Geode Capital Management LLC lifted its holdings in UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after buying an additional 34,248 shares during the period. Vestal Point Capital LP purchased a new stake in UroGen Pharma during the third quarter worth $5,080,000. Finally, Rice Hall James & Associates LLC increased its holdings in shares of UroGen Pharma by 273.6% in the 3rd quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock valued at $3,453,000 after acquiring an additional 199,110 shares during the period. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.